ConvaTec Group Plc
Results of Annual General Meeting
Reading, United Kingdom 7 May 2020 - Poll Result
ConvaTec Group Plc ("ConvaTec"), a leading global medical products and technologies company, held its annual general meeting today ("Meeting"), The results of the poll held in relation to the resolutions proposed at the Meeting are set out below.
|
For (see note 2) |
Against (see note 2) |
Total Votes |
% of ISC Voted |
Number of Votes Withheld (see note 3 |
|||
Resolution |
No of shares |
% |
No of Shares |
% |
||||
1 |
Receive Annual Report and Accounts |
1,689,253,478 |
99.99 |
162,424 |
0.01 |
1,689,415,902 |
85.17 |
1,375,861 |
2 |
Approve the Directors' Remuneration Report |
1,459,271,427 |
86.35 |
230,658,135 |
13.65 |
1,689,929,562 |
85.20 |
908,684 |
3 |
Approve the Directors' Remuneration Policy |
1,479,320,219 |
87.54 |
210,611,343 |
12.46 |
1,689,931,562 |
85.20 |
906,684 |
4 |
Declare Final Dividend |
1,670,311,992 |
98.79 |
20,526,249 |
1.21 |
1,690,838,241 |
85.24 |
6 |
5 |
Elect John McAdam as a director |
1,686,038,868 |
99.72 |
4,725,844 |
0.28 |
1,690,764,712 |
85.24 |
73,534 |
6 |
Elect Karim Bitar as a director |
1,687,089,831 |
99.78 |
3,746,388 |
0.22 |
1,690,836,219 |
85.24 |
2,028 |
7 |
Elect Brian May as a director |
1,689,080,374 |
99.90 |
1,749,450 |
0.10 |
1,690,829,824 |
85.24 |
8,423 |
8 |
Re-elect Frank Schulkes as a director |
1,684,095,328 |
99.60 |
6,734,291 |
0.40 |
1,690,829,619 |
85.24 |
8,628 |
9 |
Re-elect Margaret Ewing as a director |
1,662,219,417 |
98.31 |
28,611,702 |
1.69 |
1,690,831,119 |
85.24 |
7,128 |
10 |
Re-elect Rick Anderson as a director |
1,686,272,799 |
99.73 |
4,561,920 |
0.27 |
1,690,834,719 |
85.24 |
3,528 |
11 |
Re-elect Regina Benjamin as a director |
1,678,521,751 |
99.30 |
11,891,727 |
0.70 |
1,690,413,478 |
85.22 |
424,768 |
12 |
Re-elect Ros Rivaz as a director |
1,630,402,633 |
96.47 |
59,672,747 |
3.53 |
1,690,075,380 |
85.21 |
762,866 |
13 |
Re-elect Sten Scheibye as a director |
1,687,084,151 |
99.78 |
3,745,468 |
0.22 |
1,690,829,619 |
85.24 |
8,628 |
14 |
Re-appoint Deloitte LLP as auditor |
1,690,827,240 |
100.00 |
9,746 |
0.00 |
1,690,836,986 |
85.24 |
1,261 |
15 |
Authorise the directors to determine the remuneration of the Company's auditor |
1,690,692,456 |
100.00 |
5,000 |
0.00 |
1,690,697,456 |
85.24 |
140,791 |
16 |
Authorise political donations and political expenditure |
1,679,778,558 |
99.35 |
11,050,957 |
0.65 |
1,690,829,515 |
85.24 |
8,732 |
17 |
Authorise allotment of shares |
1,576,731,448 |
93.28 |
113,598,212 |
6.72 |
1,690,329,660 |
85.22 |
508,587 |
18 |
Disapply pre-emption rights* |
1,665,615,258 |
98.53 |
24,844,432 |
1.47 |
1,690,459,690 |
85.23 |
378,557 |
19 |
Disapply pre-emption rights in connection with an acquisition or specified capital investment* |
1,664,010,440 |
98.44 |
26,449,249 |
1.56 |
1,690,459,689 |
85.23 |
378,557 |
20 |
Authorise purchase of own shares* |
1,669,151,425 |
98.76 |
20,937,729 |
1.24 |
1,690,089,154 |
85.21 |
749,092 |
21 |
Call general meetings on 14 days' notice* |
1,663,148,185 |
98.36 |
27,687,156 |
1.64 |
1,690,835,341 |
85.24 |
2,906 |
*Special Resolution
NOTES:
1. All resolutions were passed.
2. Votes "For" and "Against" are expressed as a percentage of votes received.
3. A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
4. Total number of shares in issue at close of business on 6 May 2020 was 1,983,513,851 shares; 85.24% of voting capital was instructed.
5. Computershare acted as scrutineer of the poll on all resolutions.
In accordance with Listing Rule 9.6.2, copies of the resolutions that do not constitute ordinary business that were passed at the Meeting will be submitted to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
Enquiries
Analysts and Investors
Mark Reynolds, Director Investor Relations, ConvaTec +44 (0)7551 036 625
Media
Buchanan: Charles Ryland / Chris Lane / Vicky Hayns +44 (0)207 466 5000
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
# # #
END